Methods and Applications of Antiosteoporosis Assays

[1]  Ting Han,et al.  Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. , 2008, Journal of ethnopharmacology.

[2]  Xianlong Zhang,et al.  Substance P stimulates production of interleukin 1beta and tumor necrosis factor alpha in fibroblasts from hip periprosthetic membrane. , 2008, The Journal of arthroplasty.

[3]  M. Skalicky,et al.  Bone structure and metabolism in a rodent model of male senile osteoporosis , 2007, Experimental Gerontology.

[4]  S. Kadota,et al.  Triterpenoids from Cimicifugae rhizoma, a novel class of inhibitors on bone resorption and ovariectomy-induced bone loss. , 2007, Maturitas.

[5]  Guoqiang Chen,et al.  The effect of 3-hydroxybutyrate on the in vitro differentiation of murine osteoblast MC3T3-E1 and in vivo bone formation in ovariectomized rats. , 2007, Biomaterials.

[6]  Ming Zhao,et al.  Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates. , 2007, Journal of medicinal chemistry.

[7]  Jeff T Roesgen,et al.  Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. , 2006, Bioorganic & medicinal chemistry letters.

[8]  A. Díez-Pérez,et al.  In vitro functional assay of alleles and haplotypes of two COL1A1-promoter SNPs. , 2005, Bone.

[9]  Fupeng Ma,et al.  In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor. , 2005, Bioorganic & medicinal chemistry.

[10]  Theo de Boer,et al.  Development and validation of fluorescent receptor assays based on the human recombinant estrogen receptor subtypes alpha and beta. , 2004, Journal of pharmaceutical and biomedical analysis.

[11]  P. Delmas,et al.  An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. , 2002, Bone.

[12]  S. Mohan,et al.  A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. , 2002, Bone.

[13]  C. Christiansen,et al.  Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. , 2002, Bone.

[14]  L. Galzigna,et al.  Comparison of commercial osteocalcin assay kits in evaluating osteoporosis , 1995 .